Supplementary Table S2 from Application of Genomic Sequencing to Refine Patient Stratification for Adjuvant Therapy in Renal Cell Carcinoma

Supplementary Table S2 from Application of Genomic Sequencing to Refine Patient Stratification for Adjuvant Therapy in Renal Cell Carcinoma

<p>Somatic mutations detected in 12 interrogated genes for cohorts C1-C3</p>

Saved in:

書目詳細資料
主要作者:	Naveen S. Vasudev (15057037) (author)
其他作者:	Ghislaine Scelo (15057040) (author), Kate I. Glennon (15057043) (author), Michelle Wilson (15057046) (author), Louis Letourneau (15057049) (author), Robert Eveleigh (15057052) (author), Nazanin Nourbehesht (15057055) (author), Madeleine Arseneault (15057058) (author), Antoine Paccard (15057061) (author), Lars Egevad (15057064) (author), Juris Viksna (15057067) (author), Edgars Celms (15057070) (author), Sharon M. Jackson (15057073) (author), Behnoush Abedi-Ardekani (15057076) (author), Anne Y. Warren (15057079) (author), Peter J. Selby (15057082) (author), Sebastian Trainor (15057085) (author), Michael Kimuli (15057088) (author), Jon Cartledge (15057091) (author), Naeem Soomro (15057094) (author), Adebanji Adeyoju (15057097) (author), Poulam M. Patel (15057100) (author), Magdalena B. Wozniak (15057103) (author), Ivana Holcatova (15057106) (author), Antonin Brisuda (15057109) (author), Vladimir Janout (15057112) (author), Estelle Chanudet (15057115) (author), David Zaridze (15057118) (author), Anush Moukeria (15057121) (author), Oxana Shangina (15057124) (author), Lenka Foretova (15057127) (author), Marie Navratilova (15057130) (author), Dana Mates (15057133) (author), Viorel Jinga (15057136) (author), Ljiljana Bogdanovic (15057139) (author), Bozidar Kovacevic (15057142) (author), Anne Cambon-Thomsen (15057145) (author), Guillaume Bourque (15057148) (author), Alvis Brazma (15057151) (author), Jörg Tost (10726607) (author), Paul Brennan (14943829) (author), Mark Lathrop (15057154) (author), Yasser Riazalhosseini (15057157) (author), Rosamonde E. Banks (15057160) (author)
出版:	2025
主題:	Cancer Cancer Detection and Diagnosis Therapeutic Research and Development Clinical Research and Trials Biomarkers Genetic biomarkers Prognostic biomarkers Genitourinary Cancers Renal cancer Precision Medicine Translational Research
標簽:	添加標簽沒有標簽, 成為第一個標記此記錄!

相似書籍

Supplementary Table S1 from Application of Genomic Sequencing to Refine Patient Stratification for Adjuvant Therapy in Renal Cell Carcinoma
由: Naveen S. Vasudev (15057037)
出版: (2025)

Figure S1 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
由: Laura Boucai (15054310)
出版: (2025)

Figure S2 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
由: Laura Boucai (15054310)
出版: (2025)

Figure S3 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
由: Laura Boucai (15054310)
出版: (2025)

Figure S4 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
由: Laura Boucai (15054310)
出版: (2025)

Table S1 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
由: Laura Boucai (15054310)
出版: (2025)

Table S2 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
由: Laura Boucai (15054310)
出版: (2025)

Table S3 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
由: Laura Boucai (15054310)
出版: (2025)

Table S4 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
由: Laura Boucai (15054310)
出版: (2025)

Table S5 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
由: Laura Boucai (15054310)
出版: (2025)

Table S6 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
由: Laura Boucai (15054310)
出版: (2025)

Supplementary Tables S1-S5 from Novel Genomic Risk Stratification Model for Primary Gastrointestinal Stromal Tumors (GIST) in the Adjuvant Therapy Era
由: Josephine K. Dermawan (17079555)
出版: (2025)

Supplementary Tables S1-S15 from Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells
由: Iris van 't Erve (15054503)
出版: (2025)

Supplementary Figure S1 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
由: Tobias Kessler (17079209)
出版: (2025)

Supplementary Figure S2 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
由: Tobias Kessler (17079209)
出版: (2025)

Supplementary Figure S3 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
由: Tobias Kessler (17079209)
出版: (2025)

Supplementary Figure S4 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
由: Tobias Kessler (17079209)
出版: (2025)

Supplementary Figure S5 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
由: Tobias Kessler (17079209)
出版: (2025)

Supplementary Figure S6 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
由: Tobias Kessler (17079209)
出版: (2025)

Supplementary Figure S7 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
由: Tobias Kessler (17079209)
出版: (2025)

Supplementary Table 2 from Somatic Exonic Deletions in <i>RUNX1</i> Constitutes a Novel Recurrent Genomic Abnormality in Acute Myeloid Leukemia
由: Anna Eriksson (15352461)
出版: (2025)

Supplementary Table1 from Somatic Exonic Deletions in <i>RUNX1</i> Constitutes a Novel Recurrent Genomic Abnormality in Acute Myeloid Leukemia
由: Anna Eriksson (15352461)
出版: (2025)

Figure S1 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
由: Nicolas A. Giraldo (15050937)
出版: (2025)

Figure s2 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
由: Nicolas A. Giraldo (15050937)
出版: (2025)

Supplementary Data 1 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
由: Nicolas A. Giraldo (15050937)
出版: (2025)

Supplementary Data 2 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
由: Nicolas A. Giraldo (15050937)
出版: (2025)

Supplementary Data 3 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
由: Nicolas A. Giraldo (15050937)
出版: (2025)

Supplementary Data1 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
由: Nicolas A. Giraldo (15050937)
出版: (2025)

Supplementary Table S1 from Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer
由: Emil Christensen (15054394)
出版: (2025)

Supplementary Table S2 from Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer
由: Emil Christensen (15054394)
出版: (2025)

Supplementary Table S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
由: Raphaël Leman (17314506)
出版: (2025)

Supplementary Table S2 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
由: Raphaël Leman (17314506)
出版: (2025)

Supplementary Table S3 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
由: Raphaël Leman (17314506)
出版: (2025)

Supplementary Table S4 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
由: Raphaël Leman (17314506)
出版: (2025)

Supplementary Table S5 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
由: Raphaël Leman (17314506)
出版: (2025)

Supplementary Table S6 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
由: Raphaël Leman (17314506)
出版: (2025)

Supplementary Figure S1 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
由: Rohit Thummalapalli (17314483)
出版: (2025)

Supplementary Figure S10 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
由: Rohit Thummalapalli (17314483)
出版: (2025)

Supplementary Figure S11 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
由: Rohit Thummalapalli (17314483)
出版: (2025)

Supplementary Figure S12 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
由: Rohit Thummalapalli (17314483)
出版: (2025)

Cannot write session to /tmp/vufind_sessions/sess_o8n8580if15aan7j1dl5k6bu24